Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis
Stopped Amgen decided to terminate the study early to be able to meet US regulatory timelines fo filing. Subjects in treatment were rolled over to the 20140159 study.
Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
- DRUG: Cinacalcet HCl
- DIETARY_SUPPLEMENT: Standard of Care
Sponsor
Amgen